Latest news with #GLP-1RA
Yahoo
21-05-2025
- Business
- Yahoo
Novo Nordisk and Eli Lilly Lead, but New Entrants Eye GLP-1RA Market Opportunities
Explore the GLP-1R agonists market, uncovering new opportunities for repurposing beyond type 2 diabetes and obesity. Discover insights on unmet needs, pipeline analysis, and competitive landscapes, highlighting major players like Novo Nordisk and Eli Lilly and potential new entrants. Dublin, May 21, 2025 (GLOBE NEWSWIRE) -- The "GLP-1R Agonists - Label Extensions/Drug Repurposing: Market Overview" report has been added to report is a market overview of GLP-1R agonists, focusing on their potential repurposing and label expansions in diseases outside type 2 diabetes and potential of GLP-1RAs is based on their insulin sensitization and anti-inflammatory are being investigated in different diseases in the metabolic, neurologic, and cardiologic Nordisk and Eli Lilly are currently the major players in the GLP-1RA space, but opportunity remains for new Scope Overview of GLP-1R agonists, including marketed GLP-1RAs and diseases under investigation. Analysis of unmet needs, challenges and opportunities in GLP-1RAs repurposing. Pipeline analysis and opportunity assessment of GLP-1RAs in different therapeutic areas. Overview of current major players in the GLP-1RAs space and potential future players. GLP-1RAs global market outlook and deals overview. Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the GLP-1RAs therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the GLP-1RAs therapeutics market in the future. Identify the major challenges and opportunities in the GLP-1RA space and the potential of this therapeutic class in multiple indications. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships. Key Topics Covered: 1 Preface 2 Executive Summary3 GLP-1R Agonists Overview3.1 What Are GLP-1R Agonists3.2 GLP-1R in the Body3.3 History of GLP-1R Agonists4 Industry Trends4.1 Oral GLP-1Ras4.2 Lower Dosing Frequency4.3 Combination and Dual/Triple Agonists4.4 Repurposing GLP-1Ras5 Marketed Products5.1 Global GLP-1RA Marketed Landscape5.2 Marketed GLP-1Ras5.3 Challenges and Opportunities in GLP-1RA Repurposing5.4 Key Opinion Leader Perspectives on GLP-1RA Unmet Needs6 Pricing and Reimbursement Assessment Case Study: Ozempic7 Pipeline Analysis7.1 Top 20 Indications with GLP-1RAs in Development7.2 Top Five Therapeutic Areas with the Most GLP-1RA Pipeline Assets7.3 GLP-1RA Pipeline Candidates7.4 Where Are GLP-1RAs Expected to Position in the Future Chronic Kidney Disease Treatment Landscape?7.5 Where Are GLP-1RAs Expected to Position in the Future Heart Failure Treatment Landscape?7.6 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment for Heart Failure and Chronic Kidney Disease7.7 GLP-1RA Opportunities Beyond Planned Label Expansions7.8 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment of Polycystic Ovary Syndrome8 Opportunities and Challenges8.1 Opportunities: the Role of GLP-1RAs in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis8.2 Opportunities: GLP-1RAs in Liver Diseases8.3 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment of Liver Diseases8.4 Opportunities: the Role of GLP-1RAs in Neurodegenerative Diseases8.5 Opportunities: GLP-1RAs in Central Nervous System Disorders8.6 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment of Parkinson's Disease8.7 Opportunities: the Role of GLP-1RAs in Diastolic Heart Failure and Stroke8.8 Opportunities: GLP-1RAs in Cardiovascular Diseases8.9 Opportunities: the Role of GLP-1RAs in Chronic Kidney Disease8.10 Opportunities: GLP-1RAs in Other Diseases9 Companies9.1 Current Major Player: Novo Nordisk9.2 Current Major Player: Eli Lilly9.3 Potential Future Players9.4 Key Opinion Leader Perspectives on Future Players in the GLP-1RA Space10 Market Outlook and Deals10.1 GLP-1RA Global Market10.2 Top 20 Major Deals and Acquisitions Between 2022 and 2025 with GLP-1RasCompany Coverage Includes: Novo Nordisk AS Eli Lilly and Co Shanghai Minwei Biotechnology Co Ltd Metsera Inc Sihuan Pharmaceutical Holdings Group Ltd Hanmi Pharmaceuticals Co Ltd Jiangsu Hengrui Medicine Co Ltd AstraZeneca Plc PegBio Co Ltd Beijing QL Biopharmaceutical Co Ltd Sciwind Biosciences Co Ltd U.S. National Institutes of Health Boehringer Ingelheim International GmbH i2O Therapeutics Inc Zhejiang Doer Biologics Corp CSPC Pharmaceutical Group Ltd Peptron Inc Carmot Therapeutics Inc Amogen Pharma Pvt Ltd BioLingus AG The United Laboratories International Holdings Ltd Tonghua Dongbao Pharmaceutical Co Ltd Annovis Bio Inc ImmunoForge Co Ltd Biogenomics Ltd China Pharmaceutical University Zhejiang Heze Pharmaceutical Technology Co Ltd Zhuhai United Laboratories Co Ltd Hangzhou Jiuyuan Gene Engineering Co Ltd Structure Therapeutics Inc Altimmune Inc Chia Tai Tianqing Pharmaceutical Group Co Ltd Gmax Biopharm LLC Guangzhou Dazhou Biomedical Technology Co Ltd Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd Huadong Medicine Co Ltd Innovent Biologics Inc Merck & Co Inc Neuraly Inc Onegene Biotechnology Inc Protheragen Inc RenaissThera Pvt Ltd Sekkei Inc Uni-Bio Science Group Ltd HEC Pharma Co Ltd Jiangsu Hansoh Pharmaceutical Group Co Ltd Cascade Pharmaceuticals Inc D&D Pharmatech Co Ltd Huons Global Co Ltd Immunwork Inc Leto Laboratories Co Ltd MetaVia Inc Pfizer Inc Qilu Regor Therapeutics Inc Sanofi Xintrum Pharmaceuticals Ltd Gan & Lee Pharmaceuticals Co Ltd Adocia SAS AnyGen Co Ltd Ascendis Pharma AS AULBIO Co Ltd BrightGene Bio-Medical Technology Co Ltd Camurus AB HK inno.N Corp Hybio Pharmaceutical Co Ltd IGC Pharma Inc Lancaster University Laxxon Medical GmbH Poolbeg Pharma Plc ProGen Co Ltd Septerna Inc Shanghai Innogen Pharmaceutical Technology Co Ltd Shenzhen Salubris Pharmaceuticals Co Ltd Sun Pharmaceutical Industries Ltd Suzhou Wingtech Pharmaceutical Technology Co Ltd Theertha Biopharma Pvt Ltd Verdiva Bio Ltd Vivani Medical Inc Yunovia Co Ltd Adare Pharma Solutions Amgen Inc Apeloa Pharmaceutical Co Ltd ApicHope Pharmaceutical Co Ltd Arecor Therapeutics Plc Biolexis Therapeutics Inc Biomea Fusion Inc Biomed Industries Inc BioNxt Solutions Inc California Institute for Biomedical Research China Medical System Holdings Ltd Chongqing Chenan BioPharm Co Ltd CinFina Pharma LLC Crinetics Pharmaceuticals Inc CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd Daewoong Therapeutics Inc Diabetology (Products) Ltd Dx&Vx Efil Bioscience Inc Entera Bio Ltd Gilead Sciences Inc Guangzhou BeBetter Medicine Technology Co Ltd HangZhou HuiSheng Biotech Pharmaceutical Co Ltd Hepagene Therapeutics Inc HighField Biopharmaceuticals, Inc. Hua Medicine Shanghai Ltd INVENT Pharmaceuticals Inc Inventage Lab Inc iX Biopharma Ltd Jiangsu Normal University Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd Livzon Pharmaceutical Group Inc MeiraGTx Holdings Plc MindRank Ltd Niedlfree Technologies Pvt Ltd OPKO Health Inc Remedium Bio Inc Scohia Pharma Inc Shandong New Era Pharmaceutical Co Ltd SN BioScience Co Ltd Tharimmune Inc Viking Therapeutics Inc vTv Therapeutics Inc Youngene Therapeutics Co Ltd Zealand Pharma AS 4Moving Biotech Abaxys Therapeutics SA Aerami Therapeutics Holdings Inc AI Proteins Inc Akrikhin Alphamab Oncology Aprilbio Co Ltd Ascletis Pharma Inc Beijing Eastern Biotech Co Ltd Beijing SL Pharmaceutical Co Ltd Biora Therapeutics Inc Bostal Drug Delivery Co Ltd Bristol-Myers Squibb Co Chengdu Brilliant Pharmaceutical Co Ltd China Resources Double-Crane Pharmaceutical Co Ltd Closed Loop Medicine Ltd Coya Therapeutics Inc Delpor Inc Duke University Enteris BioPharma Inc G2GBIO Inc GlyTech Inc Gubra ApS Halo Therapeutics Ltd HEC Pharm Group Hualan Biological Engineering Inc Iconovo AB Icure Pharmaceutical Inc Imagine Pharma LLC Immupharma Plc Imperial College London Innopharmax Inc Jiangsu Wanbang Biochemical Pharmaceutical Group Co Ltd Kailera Therapeutics Inc Kariya Pharmaceuticals IVS Kunming Yinnuo Medical Technology Co. Ltd. Lanzhou Institute of Biological Products Co Ltd Lepu Medical Technology (Beijing) Co Ltd Mapi Pharma Ltd MBX Biosciences Inc Metaphore Biotechnologies Inc Nanexa AB National Institute of Biomedical Imaging and Bioengineering NutriBand Inc Oramed Pharmaceuticals Inc Original BioMedicals Co Ltd Pep2Tango Therapeutics Inc ProLynx LLC Qilu Pharmaceutical Co Ltd QuiaPEG Pharmaceuticals AB Rani Therapeutics LLC Rivus Pharmaceuticals Inc Rose Pharma Inc R-Pharm Sail Biomedicines Inc Shandong Boan Biotechnology Co Ltd Shanghai Fosun Pharmaceutical (Group) Co Ltd Sino Biopharmaceutical Ltd Syracuse University Terns Pharmaceuticals Inc Terry Suzhou Pharmaceutical Co Ltd The University of Adelaide Twist Bioscience Corp University of Padova University of Ulster Vanderbilt University Virtici LLC Wuxi Hebang Biotechnology Co Ltd Yichang Humanwell Pharmaceutical Co Ltd Yonsei University College of Medicine Zhejiang HuaYang Pharmaceutical Co Ltd Zhongshan Wanhan Pharmaceutical Co Ltd For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Daily Mirror
21-05-2025
- Health
- Daily Mirror
Weight loss jabs warning over protein and nutrients
People using GLP-1RA drugs are being urged to check their diets People using weight loss injections, specifically GLP-1RA drugs, are being urged to take a good look at their diet. These medications can enhance weight loss efforts, which might mislead people into believing they're living more healthily than they were before. Recent research published in Frontiers in Nutrition found that people on these medications are likely to be missing a broad array of nutrients. Protein consumption in particular was "significantly under daily needs" but people were still eating more than their recommended calories. The authors of the study have called upon healthcare practitioners to refine their dietary advice for patients on these drugs in order to avoid "unintended health consequences". They recommended nutritionists and other specialists play a part in managing a patient's journey with weight loss medications. The study spanned September to October 2024 and involved 69 participants who had been on GLP-1RA drugs for a minimum of one month. It specifically targeted people who didn't have formal meal plans or nutritional guidance programmes. The participants self-reported their food intake and interactions with healthcare providers. The results noted the average caloric intake was 1,700kcal for women and 1,933kcal for men. This is actually higher than standard advice for people on these pharmaceuticals, which typically calls for a daily intake of 1,200-1,500kcal for women and no more than 1,800kcal for men. Participants were consuming excessive amounts of fats, particularly saturated fats. On the other hand, they were significantly lacking in major nutrients like: Fibre Calcium Iron Magnesium Potassium Choline Vitamins A, C, D and E The lack of protein in their diet is a particular worry. This essential food group helps maintain your lean muscle mass during weight loss and plays a key role in metabolic health and weight management. Less than half of the respondents were meeting the minimum daily requirements for protein intake. The experts cautioned that such a lack of vital nutrients in someone's diet can lead to severe long-term effects, including deterioration of cardiovascular health and bone density. One major issue researchers identified was a lack of awareness. They discovered people often overestimate their fruit and vegetable consumption, indicating a need for better education on portion sizes. Interestingly, the study revealed no difference in dietary intake based on the duration of GLP-1RA use. A total of 39% had been using it for over a year and nearly half intended to continue its use indefinitely. This is despite the reported side effects, which included nausea, diarrhoea and fatigue. It's also suggested that these medications could influence food preferences. This might result in people eating less of certain foods. A total of 80% reported experiencing greater weight loss with these medications compared to traditional weight loss methods.
Yahoo
07-05-2025
- Business
- Yahoo
Novo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demand
Novo Nordisk has reduced its sales and profits forecasts for 2025 due to lower-than-expected demand in the US for blockbuster weight loss and diabetes drugs, though shares in the company were still up following positive Q1 results. Despite feeling the effects from the compounded glucagon-like peptide 1 receptor agonist (GLP-1RA) market, Novo Nordisk is still growing at a fast pace. Total revenues for the company came in at DKr78.1bn ($11.9bn) for Q1 2025, up 18% at constant exchange rates from the same period last year. Operating profit increased by 20%, reaching DKr38.8bn. Whilst the share price in the Copenhagen-listed company opened relatively unchanged to a pre-earnings release market close, the stock crept up 5.8% by mid-morning today (7 May). Novo Nordisk's market cap of DKr1.56tn is the second largest in Europe. The Danish pharma company's diabetes and obesity care business made up the bulk of total revenue. Sales for the unit, headed by GLP-1RA treatments Wegovy (semaglutide) and Ozempic (semaglutide) for weight loss and type 2 diabetes, respectively, reached DKr73.5bn. Novo Nordisk stated that obesity sales were the main driver – up 65% compared to Q1 2024. Diabetes sales were up a more modest 11%, with the market not as big as its burgeoning obesity counterpart. When it comes to its total 2025 outlook, Novo Nordisk does not think it will reach its previously anticipated target. The company cut its sales growth to a range of 13-21%, compared to earlier guidance of 16-24%. Operating profit growth is forecast at 16-24%, also down from a previous range of 19-27%, the company said. The reason, Novo Nordisk stated, was 'lower-than-planned penetration of branded GLP-1RA treatments in the US, impacted by compounded GLP-1RAs'. Compounding pharmacies were allowed to produce vast quantities of semaglutide copies when Novo Nordisk's branded drugs were in short supply starting in early 2022. Compounded drugs are custom-made and unbranded medications that contain the same active ingredient as a marketed drug, such as semaglutide, under a prescription. Several telehealth companies such as Mochi Health and Hims & Hers began to offer compounded semaglutide during the shortage, significantly growing their customer base in this time. Their growth in popularity has meant an erosion of market share in the obesity sector for Novo Nordisk. The Danish company has now formed a partnership to provide Him & Hers customers access to the NovoCare Pharmacy. Novo Nordsik's CEO Lars Fruergaard Jørgensen said: "In the first quarter of 2025, we delivered 18% sales growth and continued to expand the reach of our innovative GLP-1 treatments. However, we have reduced our full-year outlook due to lower-than-planned branded GLP-1 penetration, which is impacted by the rapid expansion of compounding in the US.'
Qatar Tribune
04-05-2025
- Health
- Qatar Tribune
Aamal, Novo Nordisk join forces to bring weight management drug Wegovy to Qatar
Tribune News Network Doha Ebn Sina Medical, a subsidiary of Aamal Company and a leading supplier of pharmaceutical, and Novo Nordisk, the Danish leading global healthcare company renowned for its expertise in treating chronic diseases such as diabetes and obesity, announced the availability of Wegovy (Semaglutide 2.4mg) in Qatar. The event was attended by HE Anders Bjørn Hansen, the Ambassador of Denmark to the UAE and Qatar, Aamal Company CEO Rashid Al Mansoori, in the presence of Manvendra Singh, General Manager of Novo Nordisk Qatar and Dr. Nayla Mansour, Commercial Director on behalf of Essam Faragalla, General Manager of Ebn Sina Medical. Wegovy (Semaglutide 2.4mg), the first and only once-weekly GLP-1 receptor agonist (GLP-1RA) indicated for chronic weight management in adults and adolescents ages 12 years and above1, is now available in Qatar. Obesity has emerged as a significant global epidemic, affecting approximately 1 billion individuals world-wide2. Obesity in the Gulf is rapidly unfolding with the highest rates globally3. In Qatar, the obesity crisis is particularly severe, the current prevalence of obesity (body mass index [BMI] ≥ 30 kg/m2) amongst adults in Qatar is estimated to be 41% with a notably higher prevalence amongst women (46%) and, nearly 76% of individuals in Qatar are classified as overweight; this places Qatar among the top 10 highest obesity rates in the world4,5,. The high rates of obesity and overweight in Qatar are linked to the high-country overall rates of related chronic conditions such as pre-diabetes, diabetes and cardiovascular diseases (CVDs) 6. The active ingredient in Wegovy, Semaglutide 2.4 mg, works by reducing hunger and increasing the feeling of fullness 1,7. Wegovy is indicated as adjunct to reduced calorie intake and increased physical activity for weight management, including weight loss and weight maintenance in adults with obesity (BMI ≥ 30 kg/m2) or with overweight (BMI ≥ 27 kg/m2) in the presence of at least one weight-related comorbidity. As per clinical research, Wegovy on top of diet and exercise delivers 17% mean weight loss sustained over 2 years with one third of patients having a reduction of at least 20% body weight loss 1,8,9,10. Semaglutide 2.4 mg demonstrated significant improvements in other cardiometabolic risk factors such as: waist circumference, blood pressure, lipid profile, Glycemic parameters & C-reactive protein. The SELECT clinical study including 17,604 adults with a BMI ≥27 kg/m2 demonstrated that Semaglutide 2.4 mg resulted in a statistically significant 20% risk reduction in Major Adverse Cardiovascular Events (MACE) in people with overweight or obesity and established CVD, without T2DM1,15. Besides its indication in adults, Wegovy is also approved as the first and only once weekly GLP-1 receptor agonist (GLP-1RA) for chronic weight management in adolescents with obesity from the age of 12 years1. This innovation may help transform the medical management of adolescent obesity in Qatar, where nearly 20% of children and adolescents are affected.6;11 During the event, Rashid bin Ali Al Mansoori, Aamal Company CEO, welcomed the attendees and highlighted this major step forward in addressing this public health challenge. He emphasized Aamal's commitment to advancing healthcare innovation and infrastructure in Qatar, through its subsidiaries such as Ebn Sina Medical in alignment with the country's National Health Strategy and Vision 2030, and reaffirmed Aamal's dedication to supporting access to the latest healthcare solutions that can positively impact the lives of individuals and the health of our wider community. From Novo Nordisk's side, Manvendra Singh, General Manager Novo Nordisk Qatar said: 'At Novo Nordisk, we are proud to bring over 100 years of global leadership in chronic disease management and 25 years of dedicated obesity research to Qatar. The availability of Wegovy marks a significant step in addressing obesity as a serious, chronic disease. As Qatar continues to face high rates of obesity, diabetes, and cardiovascular disease, our collaboration with Ebn Sina is vital. Together, we are committed to strengthening the healthcare landscape and improving patient outcomes through innovative, science-driven solutions.' Ebn Sina Medical General Manager Essam Faragalla added: 'At Ebn Sina Medical, we are committed to ensuring that the people of Qatar have access to world-class healthcare solutions. This partnership with Novo Nordisk marks a significant milestone in our journey to address the rising prevalence of obesity and related health complications in the country. We enjoy a long-standing relationship with Novo Nordisk and share a unified vision to prioritize patient-centric care. The introduction of Wegovy reflects our continuous drive to deliver innovative treatments and reinforces our role as a trusted healthcare partner aligned with Qatar's National Health Strategy.'
Yahoo
01-05-2025
- Business
- Yahoo
Lilly's Q1 2025 revenue jumps 45%, but CVS shift boosts Novo's Wegovy
Eli Lilly has reported $12.73bn in Q1 2025 revenue, a 45% increase from the prior year, driven largely by demand for its diabetes and obesity drugs, Mounjaro (tirzepatide) and Zepbound (tirzepatide), respectively. But the announcement was quickly overshadowed by news from rival Novo Nordisk, which disclosed that CVS Caremark – the largest US pharmacy benefit manager (PBM) – will make its weight loss drug Wegovy (semaglutide) the preferred glucagon-like receptor 1 agonist (GLP-1RA) treatment on its template formularies starting 1 July. CVS's decision is expected to expand access to Novo's weight-loss therapy, whilst limiting coverage for Lilly's Zepbound, potentially complicating the rollout of one of Lilly's fastest-growing products. CVS said the change aims to offer members 'a more affordable price'. Lilly's stock fell 6% when markets opened following the announcement on 1 May, despite its strong revenue performance. Zepbound brought in $2.31bn during the quarter, up from $517m a year ago. Meanwhile, Novo shares rose 3.6% after the CVS news. Lilly's CEO David Ricks downplayed the impact of the CVS decision to investors during the company's earnings call. 'We're not surprised that this kind of thing was announced,' Ricks said. 'Most of the growth in the category is happening with our medicine…We're not interested at all in one of the deals of reducing access and choice for doctors and patients. We want to expand it.' Ricks suggested the impact of the CVS deal may be limited, referencing the relatively low opt-in rates from employers using template formularies. 'We'll work through it. Our job will be to continue to drive [the] share and preference for our brand,' Ricks added. According to GlobalData analyst Costanza Alciati, the competitive dynamic between Wegovy and Zepbound comes down to pricing: 'Wegovy and Zepbound have similar efficacy and tolerability profiles, which means that the cost is the main determinant when it comes to competitiveness,' she said, noting that physicians tend to prescribe the more affordable option due to the high prices of GLP-1RA therapies. Alciati also pointed to regulatory and pricing pressures from US authorities as a key factor influencing these coverage deals. 'Novo Nordisk and Eli Lilly have received a lot of pressure, especially from the US government, to reduce obesity drugs prices, thus these deals with pharmacies and healthcare authorities are a way to offer discounts to patients and gain some competitive edge over each others.' Still, she noted that Eli Lilly may be playing the long game. 'It may be that Eli Lilly is not concerned as it has strong candidates in the pipeline,' she said. Among them are its oral GLP-1RA drug orforglipron and retatrutide, which have shown strong clinical results, while Novo's once-promising CagriSema underperformed in recent trials. Last month, Lilly shared positive data from the Phase III trial of orforglipron. The drugmaker expects to file for the drug's approval in obesity by the end of 2025 and type 2 diabetes in 2026. If it gains market approval, GlobalData projects sales of orforglipron to reach $11.8bn in 2030. GlobalData is the parent company of Pharmaceutical Technology. Lilly reaffirmed its full-year 2025 revenue guidance of $58bn to $61bn, which does not yet reflect proposed tariffs on pharmaceutical imports. "Lilly's Q1 2025 revenue jumps 45%, but CVS shift boosts Novo's Wegovy" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
